Science Explorer Back to mapMap
Discussion
Researcher · Simcere Pharmaceutical (China) · China

Mingzhe Xiao

Mingzhe Xiao publishes mostly in Pulmonary and Respiratory Medicine, Oncology and Molecular Biology, on topics such as Lung Cancer Treatments and Mutations, Cancer Genomics and Diagnostics and Cancer Immunotherapy and Biomarkers.

OpenAlex
World rank
#5,906,743
of 7,710,434 ranked researchers
Rank in China
#840,332
of 978,568
Works
68
Citations
503
Citations per work
7.4
h-index
8
i10-index 8Top 64% in Pulmonary and Respiratory Medicine
Mingzhe Xiao

What does Mingzhe Xiao research?

Mingzhe Xiao's work is mostly in Medicine (61%), Biochemistry, Genetics and Molecular Biology (29%).

Health Sciences: 41 works · 60.6% of their workMedicine: 41 works · 60.6% of their workPulmonary and Respiratory Medicine: 19 works · 27.3% of their workOncology: 16 works · 23.2% of their workSurgery: 6 works · 8.1% of their workRadiology, Nuclear Medicine and Imaging: 1 works · 2.0% of their workLife Sciences: 20 works · 28.7% of their workBiochemistry, Genetics and Molecular Biology: 20 works · 28.7% of their workMolecular Biology: 10 works · 14.6% of their workCancer Research: 10 works · 14.1% of their workEverything else: 7 works · 10.7% of their workTHEIR WORKMingzhe Xiao68works
Life Sciences29%Health Sciences61%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Medicine4160.6%
    1. Biochemistry, Genetics and Molecular Biology2028.7%
  3. Everything else710.7%
  1. 1Pulmonary and Respiratory Medicine27% of their works
  2. 2Oncology23% of their works
  3. 3Molecular Biology15% of their works
  4. 4Cancer Research14% of their works
  5. 5Surgery8% of their works
  6. 6Radiology, Nuclear Medicine and Imaging2% of their works

Research topics

Which keywords describe Mingzhe Xiao's research?

The keywords of their largest research topics: Targeted Therapy, Clinical Trials, Tumor Microenvironment, ALK Inhibitors, EGFR Mutations, Cancer Genomics, Mutational Signatures and Chemotherapy.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 20 words, with their numbers
  1. Targeted Therapy563 topics
  2. Clinical Trials352 topics
  3. Tumor Microenvironment302 topics
  4. ALK Inhibitors231 topic
  5. EGFR Mutations231 topic
  6. Cancer Genomics211 topic
  7. Mutational Signatures211 topic
  8. Chemotherapy182 topics
  9. Immune Checkpoint Blockade171 topic
  10. PD-1 and PD-L1171 topic
  11. Cancer131 topic
  12. Ferroptosis131 topic
  13. Genomic Profiles121 topic
  14. Small-Cell Lung Cancer121 topic
  15. RNA methylation91 topic
  16. m6A-seq91 topic
  17. CT Screening61 topic
  18. Lung Cancer61 topic
  19. Lung Tumors51 topic
  20. Metastatic Carcinomas51 topic

Where does Mingzhe Xiao work?

Mingzhe Xiao's main affiliation in the publication record is Simcere Pharmaceutical (China), China.

How many publications and citations does Mingzhe Xiao have?

OpenAlex counts 68 works and 503 citations for Mingzhe Xiao, an h-index of 8, ranking #5,906,743 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Mingzhe Xiao. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.